Suppr超能文献

伊诺努大学肝细胞癌的肝移植

Liver Transplantation for Hepatocellular Carcinoma at Inonu University.

作者信息

Kayaalp Cuneyt, Ince Volkan, Ersan Veysel, Karakas Serdar, Kahraman Aysegul Sagir, Yilmaz Sezai

机构信息

Inonu University Liver Transplantation Institute, 44315, Malatya, Turkey.

出版信息

J Gastrointest Cancer. 2017 Sep;48(3):268-271. doi: 10.1007/s12029-017-9965-2.

Abstract

There is a great effort in the world to find a new drug in hepatocellular carcinoma (HCC) treatment. Turkey has a limited number of basic science studies to discover a new therapeutic drug for HCC. It seems that Turkey is distanced from the global drug discovery race and competition, however, Turkey has the advantage of a wide experience in living donor liver transplantation, like South Korea and Japan. Turkey can plan new studies on HCC, particularly with living donor liver transplantation. Neoadjuvant treatment methods before living donor liver transplantation for advanced tumors would be a good idea for study in Turkey. Because Inonu University has the busiest liver transplantation program in Turkey, the contribution of Inonu University to trials like this can improve the depth of the studies. To conclude, the Inonu University Liver Transplantation Institute has the busiest program in Turkey with 1,600 transplantations in eight years. The program is based on living donor liver transplantations (80%). Living donor liver transplantation for advanced HCC patients is our favorite topic to study.

摘要

全球正在付出巨大努力寻找用于肝细胞癌(HCC)治疗的新药。土耳其开展的旨在发现治疗HCC新药的基础科学研究数量有限。土耳其似乎远离了全球药物研发的竞争,但土耳其与韩国和日本一样,在活体肝移植方面有着丰富经验。土耳其可以规划关于HCC的新研究,特别是与活体肝移植相关的研究。对于晚期肿瘤患者,在活体肝移植前采用新辅助治疗方法将是土耳其值得研究的一个好方向。由于伊诺努大学拥有土耳其最繁忙的肝移植项目,伊诺努大学对这类试验的贡献能够提升研究的深度。总之,伊诺努大学肝移植研究所拥有土耳其最繁忙的项目,在八年时间里完成了1600例移植手术。该项目以活体肝移植为主(占80%)。针对晚期HCC患者进行活体肝移植是我们最喜欢研究的课题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验